



# ANNUAL SMALL CELL LUNG CANCER RESEARCH CONSORTIUM MEETING

March 15 and 16, 2018  
NCI Shady Grove  
Rockville, MD

# Members

The NCI Small Cell Lung Cancer Consortium brings together members from institutions across the US to accelerate progress against this deadly disease.

- **Charles Rudin**, Memorial Sloan Kettering
- **Nikolaus Schultz**, Memorial Sloan Kettering
- **Andrea Ventura**, Memorial Sloan Kettering
- **Elizabeth Simon**, Memorial Sloan Kettering
- **Adi Gazdar**, UT Southwestern Medical Center
- **Lynne Berry**, Vanderbilt University
- **Tyler Jacks**, Massachusetts Institute of Technology
- **Anna Farago**, Massachusetts General Hospital
- **Peter Ujhazy**, National Cancer Institute
- **Suzanne Forry**, National Cancer Institute
- **Anish Thomas**, National Cancer Institute
- **Kwok-Kin Wong**, New York University
- **Camilla Christensen**, Dana-Farber Cancer Institute
- **Kwon Park**, University of Virginia
- **David MacPherson**, Fred Hutchinson Cancer Research Center
- **Samir Hanash**, The University of Texas MD Anderson Cancer Center
- **Trudy Oliver**, University of Utah
- **Michael Berger**, Memorial Sloan Kettering
- **John Poirier**, Memorial Sloan Kettering
- **Scott Lowe**, Memorial Sloan Kettering
- **John Minna**, UT Southwestern Medical Center
- **Yu Shyr**, Vanderbilt University
- **Patrick Nana-Sinkam**, Virginia Commonwealth University
- **Afshin Dowlati**, Case Western Reserve University
- **Beverly Teicher**, National Cancer Institute
- **Eva Szabo**, National Cancer Institute
- **Yves Pommier**, National Cancer Institute
- **James Lee**, Ohio State University
- **Nathanael Gray**, Dana-Farber Cancer Institute
- **Jeffrey Kern**, National Jewish Health
- **Julien Sage**, Stanford University
- **Lauren Byers**, The University of Texas MD Anderson Cancer Center
- **John Heymach**, The University of Texas MD Anderson Cancer Center
- **Harold Varmus**, Weill Cornell Medicine

# Members


The NCI Small Cell Lung Cancer Consortium brings together members from institutions across the US to accelerate progress against this deadly disease.

- **Charles Rudin**, Memorial Sloan Kettering
- **Nikolaus Schultz**, Memorial Sloan Kettering
- **Andrea Ventura**, Memorial Sloan Kettering
- **Elizabeth Simon**, Memorial Sloan Kettering
- **Adi Gazdar**, UT Southwestern Medical Center
- **Lynne Berry**, Vanderbilt University
- **Tyler Jacks**, Massachusetts Institute of Technology
- **Anna Farago**, Massachusetts General Hospital
- **Peter Uihazy**, National Cancer Institute
- **Suzanne Forry**, National Cancer Institute
- **Anish Thomas**, National Cancer Institute
- **Kwok-Kin Wong**, New York University
- **Camilla Christensen**, Dana-Farber Cancer Institute
- **Kwon Park**, University of Virginia
- **David MacPherson**, Fred Hutchinson Cancer Research Center
- **Samir Hanash**, The University of Texas MD Anderson Cancer Center
- **Trudy Oliver**, University of Utah
- **Michael Berger**, Memorial Sloan Kettering
- **John Poirier**, Memorial Sloan Kettering
- **Scott Lowe**, Memorial Sloan Kettering
- **John Minna**, UT Southwestern Medical Center
- **Yu Shyr**, Vanderbilt University
- **Patrick Nana-Sinkam**, Virginia Commonwealth University
- **Afshin Dowlati**, Case Western Reserve University
- **Beverly Teicher**, National Cancer Institute
- **Eva Szabo**, National Cancer Institute
- **Ives Fommier**, National Cancer Institute
- **James Lee**, Ohio State University
- **Nathanael Gray**, Dana-Farber Cancer Institute
- **Jeffrey Kern**, National Jewish Health
- **Julien Sage**, Stanford University
- **Lauren Byers**, The University of Texas MD Anderson Cancer Center
- **John Heymach**, The University of Texas MD Anderson Cancer Center
- **Harold Varmus**, Weill Cornell Medicine

What Brought Us Here?



# SCLC PUBLICATIONS BY YEAR



# SCLC PUBLICATIONS BY YEAR

Etoposide  
Cisplatin

600

500

400

300

100

0


1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018



# SCLC PUBLICATIONS BY YEAR




# SCLC PUBLICATIONS BY YEAR





# SCLC PUBLICATIONS BY YEAR





## Preface

### Small cell lung cancer: updates and new concepts

Peter Ujhazy, O. Wolf Lindwasser

PDF Pages: 1-3

Full Text

[Get Permission](#)

## Review Articles on Small Cell Lung Cancer: New Models, Markers and Beyond

### Transcriptional deregulation underlying the pathogenesis of small cell lung cancer

Dong-Wook Kim, Keun-Cheol Kim, Kee-Beom Kim, Colin T. Dunn, Kwon-Sik Park

PDF Pages: 4-20

Full Text

[Get Permission](#)

### Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models

Yan Ting Shue, Jing Shan Lim, Julien Sage

PDF Pages: 21-31

Full Text

[Get Permission](#)

## Original Article on Small Cell Lung Cancer: New Models, Markers and Beyond

### Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes

Wei Zhang, Luc Girard, Yu-An Zhang, Tomohiro Haruki, Mahboubeh Papari-Zareei, Victor Stastny, Hans K. Ghayee, Karel Pacak, Trudy G. Oliver, John D. Minna, Adi F. Gazdar

PDF Pages: 32-49

Full Text

[Get Permission](#)

## Review Articles on Small Cell Lung Cancer: New Models, Markers and Beyond

### Targeting DNA damage repair in small cell lung cancer and the biomarker landscape

Triparna Sen, Carl M. Gay, Lauren Averett Byers

PDF Pages: 50-68

Full Text

[Get Permission](#)

### Current standards for clinical management of small cell lung cancer


Anna F. Farago, Florence K. Keane

PDF Pages: 69-79


Full Text

[Get Permission](#)

# SCLC PUBLICATIONS BY YEAR



## SCLC PUBLICATIONS BY YEAR









# Bibliometric Analysis by NIH iTrans


Total Pubs	Pubs/Year	Ave. Human	Ave. Animal	Ave. Mol/Cell	Approx. Potent'l Transl.	Cited by Clin.
5761	250.48	0.69	0.06	0.10	0.29	1798

# Bibliometric Analysis by NIH iTrans

Total Pubs	Pubs/Year	Ave. Human	Ave. Animal	Ave. Mol/Cell	Approx. Potent'l Transl.	Cited by Clin.
5761	250.48	0.69	0.06	0.10	0.29	1798



# SCLC PUBLICATIONS BY YEAR



February 13, 2018 (iSearch)

Other  
Topics

Overall  
Survival

Cell  
Carcinoma

Limited  
Stage

Cell  
Lines

Prognostic  
Factors

Prophylactic  
Cranial  
Irradiation

Mg M

Extensive  
Stage

Lymph  
Node

Tyrosine  
Kinase

CT  
Scans

Neuroendocrine  
Tumors

Paraneoplastic  
Syndrome

Central  
Nervous  
System

Virus

DNA  
Damage

Colorectal  
Cancer

Renal  
Failure

Therapeutic  
Index

Right  
Lower  
Lobe

Limbic  
Encephalitis

Case-control  
Study

SCLC  
Cell Lines

ProGRP

DNA

Predclinical  
Models

Plasma  
Concentrations

Case Report

Lesions

Second Line

ED SCLC

Extensive Disease

End Point

Other Topics

Phase II Trial

Performance Status

Other Topics

Small Cell Carcinoma

LD SCLC

Long-term Survival

Progression Free Survival

Day 1

Performance Status

Radiation Therapy

Other Topics

Thoracic Radiotherapy

5-year Survival Rate

P 0.01

Survival Function

Second Line

Brain Metastases

P 0.001

Exhaustive Disease

Dependent Prognostic Factors

Multivariate Analysis

Performance Status

Day 1

Other Topics

Other Topics

Other Topics

Other Topics



March 13, 2018 (iSearch)

Other  
Topics

Overall  
Survival

Cell  
Lines

Cell  
Carcinoma

Limited  
Stage

Prognostic  
Factors

Prophylactic  
Cranial  
Irradiation

Extensive  
Stage

Breast  
Cancer

Neuroendocrine  
Tumors

Paraneoplastic  
Syndrome

Mg M

CT  
Scans

Lambert-Eaton  
Myasthenic  
Syndrome

Limbic  
Encephalitis

Immune  
Response

Central  
Nervous  
System

Lymph  
Node

Renal  
Failure

Right  
Lower Lobe

Virus

Day 1

Performance  
Status

Multivariate  
Analysis

Other  
Topics

Extensive  
Disease

P 0.001

End Point

Independent  
Prognostic  
Factors

Second  
Line

Metastases

5-year  
Survival  
Rate

LD  
SCLC

P 0.01

Surgical  
Resection

...

Thoracic  
Radiotherapy

Other  
Topics

Prognosis  
Status

Radiation  
Therapy

Progression  
Free  
Survival

LD  
SCLC

Small Cell  
Carcinoma

...

Long-term  
Survival

Day 1

Neuroendocrine  
Carcinoma

Other  
Topics

Squamous  
Cell  
Carcinoma

Brain  
Metastases

Extensive  
Disease

...

Solid  
Tumors

...

Radiation  
Therapy

Growth  
Factor

Prostate  
Cancer

P  
0.001

Progression  
Free  
Survival

LD  
SCLC

Early  
Stage

Day 1

...

...

...

Extensive  
Disease

LD  
SCLC

...

...

...

...

Human  
SCLC

Cell  
Cycle

Cell  
Death

DNA

Growth  
Factor

...

...

...

...

...

...

SCLC  
Patients

Other  
Topics

Second  
Line

Progression  
Free  
Survival

Radiation  
Therapy

Brain  
Metastases

Phase II  
Trial

Extensive  
Disease

...

Human  
SCLC

DNA

Growth  
Factor

...

...

...

...

...

...

Cell  
Cycle

Cell  
Death

...

...







...

...

...

...

...



# Goals of the SCLC Consortium Meeting

- Updates on ongoing studies
- Finding new opportunities for collaborations, new projects
- Plans for utilization of resources provided by the Coordinating Center and the NCI
- Recognizing gaps in SCLC research
  - 2013 Priorities:
    - Better Research Tools for the Study of SCLC
    - Comprehensive Genomic Profiling of SCLC
    - New Diagnostic Approaches for SCLC
    - Therapeutic Development Efforts
    - Mechanisms Underlying Both High Rate of Initial Response and Rapid Emergence of Drug and Radiation Resistance

# Clinical Trials in SCLC

Recruiting and Not Yet Recruiting in 2018 (*clinicaltrials.gov*)

All	Phase 1	Phase 2	Phase 3	Phase 4
159	56	84	20	2

# NCI Grants in SCLC

Awarded in 2017 (*NIH IMPACII database*)

All	U24	U01	R21	R01	K99	K08	F31
18	1	7	2	5	1	1	1

# Meeting Logistics

- Internet: NIH-Guest-Network
- Cellphones on MUTE
  
- Speakers: please introduce your NCI project
- Timing of presentations
- Sharing slides?
  
- Cafeteria for lunch, closes at 2 pm
- Buses to hotel at 6:15 pm
- Tomorrow bus to NCI at 7:15 am
- Sign-up for TAXI available at the registration desk